Literature DB >> 16319025

Psychopathology in amyotrophic lateral sclerosis: a preliminary study with 27 ALS patients.

Catherine Bungener1, Ambre Piquard, Pierre-François Pradat, François Salachas, Vincent Meininger, Lucette Lacomblez.   

Abstract

Considering the few studies published on the psychopathology of ALS patients, we carried out a preliminary study evaluating depression, anxiety, emotional reactions and coping strategies in such patients. Twenty-seven ALS patients were included and evaluated using a semi-structured interview, after which they were asked to complete a questionnaire. The rater asessed the DSM-IV criteria for a major depressive episode, dysthymia and generalized anxiety, using the MADRS scale for depression, the Covi anxiety scale and the Depressive Mood scale. Subsequently, patients completed the Ways of Coping checklist. Patients were neither anxious nor depressed. Patients whose diagnosis was recent (less than six months) presented greater emotional deficit. Patients younger than 50 years of age used problem focused strategies more frequently. Those having received the diagnosis in the preceeding six months used emotion focused strategies significantly more often.The absence of characterized depression and anxiety confirmed results of the literature. The significance of this study is found in the observation of specific emotional reactions present in the first six months following diagnosis disclosure. The results show that it is useful to continue the affective evaluation of these patients and to undertake longitudinal studies starting at the time of diagnosis disclosure.

Entities:  

Mesh:

Year:  2005        PMID: 16319025     DOI: 10.1080/14660820510037863

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord        ISSN: 1466-0822


  9 in total

1.  Depression in amyotrophic lateral sclerosis.

Authors:  Elin Roos; Daniela Mariosa; Caroline Ingre; Cecilia Lundholm; Karin Wirdefeldt; Per M Roos; Fang Fang
Journal:  Neurology       Date:  2016-04-22       Impact factor: 9.910

2.  Alexithymia in Amyotrophic Lateral Sclerosis and Its Neural Correlates.

Authors:  Soumia Benbrika; Franck Doidy; Laurence Carluer; Audrey Mondou; Marie-Sonia Buhour; Francis Eustache; Fausto Viader; Béatrice Desgranges
Journal:  Front Neurol       Date:  2018-07-24       Impact factor: 4.003

3.  Emotional adjustment in amyotrophic lateral sclerosis (ALS).

Authors:  Dorothée Lulé; Sandra Pauli; Ertan Altintas; Ulrike Singer; Thomas Merk; Ingo Uttner; Niels Birbaumer; Albert C Ludolph
Journal:  J Neurol       Date:  2011-08-02       Impact factor: 4.849

Review 4.  Depression and anxiety in individuals with amyotrophic lateral sclerosis: epidemiology and management.

Authors:  Anja Kurt; Femke Nijboer; Tamara Matuz; Andrea Kübler
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

5.  A pilot study of the prevalence of psychiatric disorders in PLS and ALS.

Authors:  Edward D Huey; Jeremy Koppel; Nicole Armstrong; Jordan Grafman; Mary Kay Floeter
Journal:  Amyotroph Lateral Scler       Date:  2010-05-03

6.  Depression and quality of life in patients with amyotrophic lateral sclerosis.

Authors:  Dorothée Lulé; Sonja Häcker; Albert Ludolph; Niels Birbaumer; Andrea Kübler
Journal:  Dtsch Arztebl Int       Date:  2008-06-06       Impact factor: 5.594

7.  Depression and quality of life issues in patients with amyotrophic lateral sclerosis.

Authors:  Shannon F Stromberg; David B Weiss
Journal:  Curr Treat Options Neurol       Date:  2006-09       Impact factor: 3.972

8.  Abnormal Functional Connectivity Density in Amyotrophic Lateral Sclerosis.

Authors:  Weina Li; Jiuquan Zhang; Chaoyang Zhou; Wensheng Hou; Jun Hu; Hua Feng; Xiaolin Zheng
Journal:  Front Aging Neurosci       Date:  2018-07-17       Impact factor: 5.750

9.  Psychological flexibility and attitudes toward evidence-based interventions by amyotrophic lateral sclerosis patients.

Authors:  James R Pearlman; Einar B Thorsteinsson
Journal:  PeerJ       Date:  2019-02-26       Impact factor: 2.984

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.